Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2 Dr. Kamal Kant Kohli16 May 2022 6:15 AM GMTThe omicron (B.1.1.529) variant of SARS-CoV-2, has spread rapidly around the world and has already become the predominant variant circulating in many...
USFDA extends review of REGEN-COV to treat, prevent COVID-19: Regeneron Pharma Ruchika Sharma18 April 2022 4:30 AM GMTREGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies designed specifically to block infectivity of SARS-CoV-2 using...
Decoding REGEN-COV2 for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients Dr. Kamal Kant Kohli17 March 2022 6:15 AM GMTKidney transplant recipients are an immunocompromised population, with comorbid conditions such as obesity, diabetes, and coronary artery disease,...
Quick Review: Effectiveness of REGEN-COV antibody cocktail against B.1.617.2 (delta) variant of SARS-CoV-2 Dr. Kamal Kant Kohli1 Feb 2022 7:04 AM GMTCasirivimab plus imdevimab antibody cocktail (REGEN-COV) has been shown to reduce viral load and prevent symptomatic disease in household contacts of...
Understanding Monoclonal Antibody in Treatment of Hospitalized Patients with COVID-19 Dr. Kamal Kant Kohli18 Jan 2022 7:15 AM GMTHospitalized COVID-19 patients reported having high mortality rates (10-30%). Casirivimab and imdevimab antibody cocktail (REGEN-COV®) are authorized...
Casirivimab and Imdevimab Antibody combination for COVID-19 Prophylaxis Dr. Kamal Kant Kohli30 Nov 2021 7:03 AM GMTCasirivimab and Imdevimab are two non-competing, high-affinity human IgG1 anti-SARS- CoV-2 monoclonal antibodies, which bind specifically to the...
